ArticleDrugs - real world outcomes2024

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.

Bruno Fautrel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.